Xeris Pharmaceuticals announced this week that the company has filed an NDA (new drug application) to the FDA for its Glucagon Rescue Pen. If and when the pen is approved, it will be the first ready-to-use autoinjector of life saving glucagon to treat severe low blood sugar (hypoglycemia).
The Glucagon Rescue Pen is stable at room temperature and can be administered without any preparation or reconstitution of ingredients. These improvements in ease of use make this life-saving tool more easily administered by a range of people with minimal training.
Current glucagon formulations require the user to mix a liquid and powder in a syringe before injection. Read more about the process and make sure you’re prepared to administer glucagon here.
When it initially began clinical testing several years ago, the Xeris G-Pen was immediately dubbed the next big thing in glucagon treatment. And rightfully so. Both patients and the market have long been awaiting a quick and easy glucagon applicator to treat hypoglycemia and hypoglycemic episodes.
The Chicago-based company recently reported clinical trial data from two phase 3 studies at the American Diabetes Association’s (ADA) Scientific Sessions earlier this summer. Now, the G-Pen is nearing FDA approval and widespread market availability.
READ MORE HERE: https://beyondtype1.org/ready-to-use-glucagon-rescue-pen/